Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor

Biochemical Engineering Journal

Volumn 53, Issue 2, 2011, Pages 172-181

  Baudoin, Régis ^a   Griscom, Laurent ^b   Prot, Jean Matthieu ^a   Legallais, Cécile ^a   Leclerc, Eric ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^b CY Cergy Paris Université   (France)

Author keywords

Ammonia toxicity; HepG2 C3A; PDMS microfluidic bioreactor

Indexed keywords

AMINO ACIDS; AMMONIA; BIOCONVERSION; BIOREACTORS; CELL CULTURE; CELL PROLIFERATION; CHLORINE COMPOUNDS; DETOXIFICATION; GLUCOSE; METABOLISM; MICROFLUIDICS; SENSITIVITY ANALYSIS; TESTING; TISSUE ENGINEERING; TOXICITY;

AMMONIA CONCENTRATIONS; AMMONIA TOXICITY; CELL CONCENTRATIONS; COMPLEX ENVIRONMENTS; CULTURE CONDITIONS; ENVIRONMENTAL POLLUTANTS; HEPG2/C3A; MICROFLUIDIC BIOREACTORS;

CELLS;

AMMONIA; AMMONIUM CHLORIDE; CYTOCHROME P450 1A; GLUCOSE; GLUTAMINE;

ARTICLE; BIOREACTOR; CELL CULTURE; CELL DENSITY; CELL FUNCTION; CELL METABOLISM; DETOXIFICATION; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MICROFLUIDICS; MICROTECHNOLOGY; POLLUTANT; PRIORITY JOURNAL; TISSUE ENGINEERING;

EID: 78649912552     PISSN: 1369703X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bej.2010.10.007     Document Type: Article

References (35)

1. Stephenson J. Comparison of U.S. and Recently Enacted European Union Approaches to Protect against the Risks of Toxic Chemicals, Chemical Regulation, GAO 07-825 report. US Government Accountability Office 2007.
2. Blaauboer B.J., Andersen M.E. The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch. Toxicol. 2007, 81:385-387.
3. Greim H. Toxicological comments to the discussion about REACH. Arch. Toxicol. 2006, 80:121-124.
4. Zimmerman H.J. Acetaminophen hepatotoxicity. Clin. Liver Dis. 1998, 2:523-541.
5. De Bartolo L., Bader A. Review of a flat membrane bioreactor as a bioartificial liver. Ann. Transplant. 2001, 6:40-46.
6. De Kanter R., Monshouwer M., Meijer D., Groothuis G. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. Adapt. Curr. Drug Metabol. 2002, 3:39-59.
7. Gebhardt R., Hengstler J.G., Muller D., Glockner R., Buenning P., Laube B., Schmelzer E., Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B.R., Bader A., Langsch A., Koose T., Burger H.J., Maas J., Oesch F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 2003, 35:145-213.
8. Franklin M.R., Yost G.S. Biotransformation: a balance between bioactivation and detoxification. Principles of Toxicology: Environmental and Industrial Applications 2000, 57-86. John Wiley & Sons, New York, NY. P.L. Williams, R.C. James, S.M. Roberts (Eds.).
9. Chen H.L., Wu H.L., Fon C.C., Chen P.J., Lai M.Y., Chen D.S. Long term culture of hepatocytes from human adults. J. Biomed. Sci. 1998, 5:435-440.
10. Guillouzo A. Liver cell models in in vitro toxicology. Environ. Health Perspect. 2003, 106:511-532.
11. Baudoin R., Corlu A., Griscom L., Legallais C., Leclerc E. Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicol. In Vitro 2007, 21:535-544.
12. Viravaidya K., Sin A., Shuler M.L. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol. Prog. 2004, 20:316-323.
13. Sung J.H., Kam C., Shuler M.J. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 2010, Online.
14. Leclerc E., Sakai Y., Fujii T. Perfusion culture of fetal human hepatocytes in microfluidic-environments. Biochem. Eng. J. 2004, 20:143-148.
15. Leclerc E., Sakai Y., Fujii T. Microfluidic PDMS (polydimethylsiloxane) bioreactors for large scale culture of hepatocytes. Biotechnol. Prog. 2004, 20:750-755.
16. Park J., Berthiaume F., Toner M., Yarmush M.L., Tilles A.W. Microfabricated grooved substrates as platforms for bioartificial liver reactors. Biotechnol. Bioeng. 2005, 90:632-644.
17. Powers M.J., Janigan D., Wack K.E., Baker C.E., Stolz D.B., Griffith L. Functional behavior of primary Rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng. 2002, 8:513-527.
18. Chao P., Maguire T., Novik E., Cheng K.C., Yarmush M.L. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 2009, 78:625-632.
19. Toh Y.-C., Lim T.C., Tai D., Xiao G., van Noort D., Yu H. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 2009, 9:2026-2031.
20. Yu H., Meyvantsson I., Shkel I.A., Beebe D.J. Diffusion dependent cell behavior in microenvironments. Lab Chip 2005, 5:1089-1095.
21. Walker G.M., Zeringue H.C., Beebe D.J. Microenvironment design considerations for cellular scale studies. Lab Chip 2004, 4:91-97.
22. Charati S.G., Stern S.A. Diffusion of gases in silicone polymer: molecular dynamics simulations. Macromolecules 1998, 31:5529-5535.
23. Baudoin R., Griscom L., Monge M., Legallais C., Leclerc E. Development of a renal microchip for in vitro distal tubule models. Biotechnol. Prog. 2007, 23:1245-1253.
24. Leclerc E., Sakai Y., Fujii T. Cell culture in 3-dimensional microfluidic structure of PDMS (polydimethylsiloxane). Biomed. Microdevices 2003, 5:109-114.
25. Zanzotto A., Szita N., Boccazzi P., Lessard P., Sinskey A., Jensen K. Membrane-aerated microbioreactor for high throughput bioprocessing. Biotechnol. Bioeng. 2004, 87:243-254.
26. Schneider M., Marison I.W. The importance of ammonia in mammalian cell culture. J. Biotechnol. 1996, 46:161-185.
27. Tilles A., Baskaran H., Roy P., Yarmush M., Toner M. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotechnol. Bioeng. 2001, 73:379-389.
28. Schmitmeier S., Langsch A., Jasmund I., Bader A. Development and characterization of a small-scale bioreactor based on a bioartificial hepatic culture model for predictive pharmacological in vitro screenings. Biotechnol. Bioeng. 2006, 95:1198-1206.
29. Werlinder V., Backlund M., Zhukov A., Ingelman-Sundberg M. Transcriptional and post translational regulation of CYP1A1 by primaquine. J. Pharmacol. Exp. Ther. 2001, 297:206-214.
30. Haussinger D., Lamer W., Moorman A. Hepatocyte heterogenity in the metabolism of amino acids and ammonia. Enzyme 2002, 46:72-93.
31. Verhoeven A., Van Iwaarden J., Joseph S., Meijer A. Control of rat liver glutaminase by ammonia and pH. Eur. J. Biochem. 1983, 133:241-244.
32. Mavri Damelin D., Damelin L., Leonard H., Eaton S., Aton S., Rees M., Selden C., Hodgson H.J.F. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol. Bioeng. 2008, 99:644-651.
33. Ekwall B., Clemedson C., Ring P., Edit R.L. A new international multicentre programme to develop and evaluate batteries of in vitro tests for acute and chronic systemic toxicity. Altern. Lab. Anim. 1999, 27:339-349.
34. Lestari F., Hayes A.J., Green A.R., Markovic B. In vitro cytotoxicity of selected chemicals commonly produced during fire combustion using human cell lines. Toxicol. In Vitro 2005, 19:653-663.
35. Phillips J., Gibson W., Yam J., Alden C., Hard G. Survey of the QSAR and in vitro approaches for developing non-animal methods to supersede the in vivo LD50 test. Food Chem. Toxicol. 1990, 28:375-394.